MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of...

Full description

Saved in:
Bibliographic Details
Published in:Melanoma Res
Main Authors: Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Masedu, Francesco, Deraco, Marcello, De Manzoni, Giovanni, Chiominto, Alessandro, Valenti, Marco, Pellegrini, Cristina
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2017
Subjects:
ORIGINAL ARTICLES: Translational research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592983/
https://ncbi.nlm.nih.gov/pubmed/28486243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000367
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items